Related Experiment Video

Updated: Jun 10, 2026

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

Cetuximab in locally advanced head-and-neck cancer: defining the population

C Ho1

  • 1BC Cancer Agency–Vancouver, Vancouver, British Columbia. CHo@bccancer.bc.ca

Current Oncology (Toronto, Ont.)
|August 11, 2010
PubMed

Insights

New targeted therapies offer hope for head-and-neck squamous cell carcinoma. Cetuximab, an epidermal growth factor receptor (EGFR) inhibitor, shows promise in advanced stages, guiding treatment decisions.

Area of Science:

  • Oncology
  • Molecular Biology

Background:

  • Targeted therapy is revolutionizing head-and-neck squamous cell carcinoma (HNSCC) treatment.
  • Epidermal growth factor receptor (EGFR) is a key target in HNSCC.

Purpose of the Study:

  • To evaluate the role of cetuximab in HNSCC treatment.
  • To identify appropriate patient populations for cetuximab therapy.

Main Methods:

  • Review of Phase III clinical trial data for cetuximab.
  • Analysis of Cancer Care Ontario guideline recommendations.

Main Results:

  • Cetuximab demonstrates benefit in locally advanced and metastatic HNSCC.
  • Guidelines support EGFR-targeted therapy for stage III and IV HNSCC.

Conclusions:

  • Cetuximab represents a significant advancement in HNSCC treatment options.
  • Further assessment of patient suitability for cetuximab is warranted.
Keywords:
Head-and-neck squamous cell carcinomacetuximabcisplatinlocally advancedradiotherapy

More Related Videos

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma06:11

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Published on: April 20, 2018

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...